Press release -
SenzaGen once again makes it to the 33-list
For the second year in a row, SenzaGen takes a place on the prestigious 33-list where the magazines Ny Teknik and Affärsvärlden for the ninth time appoint the hottest young technology companies in Sweden. The presentation took place at the Munich Brewery in Stockholm on April 12.
Based at Medicon Village in Lund, SenzaGen develops and implements animal-free tests on chemicals and proteins for classification of sensitizers, primarily for the cosmetics and pharmaceutical industries. SenzaGen’s test GARD (Genomic Allergen Rapid Detection) has been developed over the last 15 years ad measures significantly more parameters than existing tests on the market, as the test is based on gene analysis in human cells. This makes GARD the safest and most efficient test. GARD has mainly been used for testing in the cosmetics industry and the EU has a ban on the testing of cosmetics on animals. In the spring of 2016, GARD has also started to be used in the pharmaceutical industry for the genetic testing of potential drugs in the early phase development.
During 2015 SenzaGen completed a new share issue of M 44 SEK in order to accelerate the company's development, scale up the sales organization, finalize the ongoing validation processes and develop new tests in GARD portfolio. The company opened a subsidiary in the US early 2016 in order to increase its market penetration.
-We appreciate the attention that making it to the 33-list gives us. Being a pioneer, breaking traditional behaviors and patterns with new technology, is challenging but so far SenzaGen has been successful. We see a large interest, a growing demand and a real need for our test in a variety of industries, says Anki Malmborg Hager, CEO of SenzaGen.
About the 33-list
The 33-list is based on nominations by companies from all over Sweden and the winners are appointed jointly by the editorial staff of the NyTeknik and Affärsvärlden. The jury looks for companies with a unique product or service based around a clear innovation with great international potential - an innovation that has the potential to change the rules of the game in their industry. To make it on the list must now be based in Sweden up to 7 years old. For more information, visit http://www.33-listan.se (In Swedish)
For more information:
Anki Malmborg Hager,
+ 46 768-284 822, amh@senzagen.com
Topics
- Economy, Finance
Categories
- awards
- business development
- animal free testing
- prices
About SenzaGen
SenzaGen provides dermal and
respiratory in vitro testing for the cosmetic, chemical and
pharmaceutical industries replacing the need for animal testing. The
company's unique test GARD is based on research from the Department of
Immune Technology at Lund University. SenzaGen is based at Medicon
Village in Lund, Sweden.
About GARD
By analyzing
200 and 389 markers, depending on the test, GARD generates massive
amounts of data and delivers results with 90 % prediction accuracy. This
can be compared to the golden standard, animal tests on mice, that
provides 72 % prediction. SenzaGen’s test also has the ability to
measure potency (strength) of a substance and can thus determine the
degree to which a substance is an allergen.
